VAW vs XBI
Vanguard Materials ETF vs SPDR S&P Biotech ETF
- • VAW has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • VAW pays a higher dividend yield (1.39%).
Side-by-side metrics
| Metric | VAW | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.39% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $4.49B | $10.73B |
YTD return | 8.48% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.91 | 1.10 |
P/E ratio | 24.08 | — |
Last price | $225.58 | $164.01 |
Inception | — | — |
Issuer | Vanguard | State Street |
VAW top holdings
| LIN | Linde PLC | 14.78% |
| NEM | Newmont Corp | 7.60% |
| FCX | Freeport-McMoRan Inc | 6.05% |
| CRH | CRH PLC | 4.67% |
| SHW | Sherwin-Williams Co | 4.58% |
| ECL | Ecolab Inc | 4.17% |
| APD | Air Products and Chemicals Inc | 3.61% |
| NUE | Nucor Corp | 3.56% |
| CTVA | Corteva Inc | 3.37% |
| VMC | Vulcan Materials Co | 2.37% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About VAW
VAW (Vanguard Materials ETF) is US materials sector stocks. Managed by Vanguard, the fund carries $4.5B in assets under management, an expense ratio of 0.09%, a dividend yield of 1.39%. Its largest holding is Linde PLC (LIN), which represents 14.8% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 8.3%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.